Home
ONC
ONC News

Latest BeiGene Ltd. American Depositary Shares (ONC) News on June 2, 2025

BeOne Medicines Unveils Promising Clinical Data for Two Novel Breast Cancer Therapies at ASCO 2025

Business Wire

4 hours ago

BeOne Medicines Unveils Promising Clinical Data for Two Novel Breast Cancer Therapies at ASCO 2025

Business Wire

2 days ago

BeOne Medicines Presents New SEQUOIA Study Results Reinforcing BRUKINSA’s Differentiated Profile with or without Venetoclax in Frontline CLL at ASCO 2025

MT Newswires

6 days ago

Sector Update: Health Care Stocks Rise Premarket Tuesday

MT Newswires

6 days ago

Sector Update: Health Care

BeOne Medicines Launches Following Redomiciliation to Switzerland, Marking a New Chapter in Global Oncology

Business Wire

6 days ago

BeOne Medicines Launches Following Redomiciliation to Switzerland, Marking a New Chapter in Global Oncology

MT Newswires

6 days ago

BeiGene Says EU Panel Recommends Tevimbra as Treatment for Nasopharyngeal Cancer

BeiGene Receives Positive CHMP Opinion for TEVIMBRA® as a First-Line Treatment for Nasopharyngeal Cancer

Business Wire

6 days ago

BeiGene Receives Positive CHMP Opinion for TEVIMBRA® as a First-Line Treatment for Nasopharyngeal Cancer

Exploring US High Growth Tech Stocks In May 2025

Simply Wall St.

11 days ago

Exploring US High Growth Tech Stocks In May 2025

BeiGene Presents Pioneering Cancer Research at ASCO 2025 – Redefining Treatment Across Hematology and Solid Tumors

Business Wire

11 days ago

BeiGene Presents Pioneering Cancer Research at ASCO 2025 – Redefining Treatment Across Hematology and Solid Tumors

BeiGene (NasdaqGS:ONC) Reveals Promising Phase 1 Trial Results Across Multiple Cancer Studies

Simply Wall St.

18 days ago

BeiGene (NasdaqGS:ONC) Reveals Promising Phase 1 Trial Results Across Multiple Cancer Studies

BeiGene Showcases Strength of Hematology Portfolio at EHA 2025 with New Data Highlighting BRUKINSA’s Leadership and Next-Generation Innovation

Business Wire

19 days ago

BeiGene Showcases Strength of Hematology Portfolio at EHA 2025 with New Data Highlighting BRUKINSA’s Leadership and Next-Generation Innovation

BeiGene to Present at the RBC Capital Markets Global Healthcare Conference

Business Wire

20 days ago

BeiGene to Present at the RBC Capital Markets Global Healthcare Conference

Trump's Plan to Cut Drug Prices Hits Pfizer, Other Pharma Stocks

The Wall Street Journal

21 days ago

Trump's Plan to Cut Drug Prices Hits Pfizer, Other Pharma Stocks

BeiGene First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag

Simply Wall St.

22 days ago

BeiGene First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag

Earnings Beat: BeiGene, Ltd. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Simply Wall St.

23 days ago

Earnings Beat: BeiGene, Ltd. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

BeiGene, Ltd. (ONC): Among Billionaire Lei Zhang’s Stock Picks with Huge Upside Potential

Insider Monkey

24 days ago

BeiGene, Ltd. (ONC): Among Billionaire Lei Zhang’s Stock Picks with Huge Upside Potential

BeiGene Ltd (ONC) Q1 2025 Earnings Call Highlights: Achieving Profitability and Expanding ...

GuruFocus.com

25 days ago

BeiGene Ltd (ONC) Q1 2025 Earnings Call Highlights: Achieving Profitability and Expanding ...

MT Newswires

25 days ago

RBC Trims Price Target on BeiGene to $311 From $312, Keeps Outperform Rating

Compared to Estimates, BeiGene (ONC) Q1 Earnings: A Look at Key Metrics

Zacks

a month ago

Compared to Estimates, BeiGene (ONC) Q1 Earnings: A Look at Key Metrics

MT Newswires

a month ago

Sector Update: Health Care Stocks Advance Pre-Bell Wednesday

MT Newswires

a month ago

BeiGene Swings to Q1 Adjusted Earnings, Revenue Increases; 2025 Revenue Outlook Reiterated

BeiGene Announces First Quarter 2025 Financial Results and Business Updates

Business Wire

a month ago

BeiGene Announces First Quarter 2025 Financial Results and Business Updates

U.S. Patent and Trademark Office Invalidates Pharmacyclics Patent Asserted Against BeiGene

Business Wire

a month ago

U.S. Patent and Trademark Office Invalidates Pharmacyclics Patent Asserted Against BeiGene

3 Stocks That Could Be Trading Below Their Estimated Fair Value

Simply Wall St.

a month ago

3 Stocks That Could Be Trading Below Their Estimated Fair Value

Will This Cancer Stock Buck Trump's Tariff Onslaught As It Nears Buy Point, Earnings?

Investor's Business Daily

a month ago

Will This Cancer Stock Buck Trump's Tariff Onslaught As It Nears Buy Point, Earnings?

Exploring 3 High Growth Tech Stocks In The US Market

Simply Wall St.

a month ago

Exploring 3 High Growth Tech Stocks In The US Market

BeiGene to Announce First Quarter 2025 Financial Results on May 7

Business Wire

2 months ago

BeiGene to Announce First Quarter 2025 Financial Results on May 7

MT Newswires

2 months ago

RBC Initiates BeiGene at Outperform With $312 Price Target

BeiGene (NasdaqGS:ONC) Gains 32% In A Quarter Amid Positive EMA Opinion On TEVIMBRA

Simply Wall St.

2 months ago

BeiGene (NasdaqGS:ONC) Gains 32% In A Quarter Amid Positive EMA Opinion On TEVIMBRA

BeiGene halts ociperlimab amid poor Phase III trial predictions

Clinical Trials Arena

2 months ago

BeiGene halts ociperlimab amid poor Phase III trial predictions

MT Newswires

2 months ago

BeiGene to Discontinue Potential Lung Cancer Treatment Study

BeiGene Provides Update on the Ociperlimab (BGB-A1217) Clinical Development Program

Business Wire

2 months ago

BeiGene Provides Update on the Ociperlimab (BGB-A1217) Clinical Development Program

MT Newswires

2 months ago

BeiGene Says EMA Panel Recommends Approval of Tevimbra for Lung Cancer

Driven Brands Holdings Among 3 Stocks Priced Below Estimated Fair Value

Simply Wall St.

2 months ago

Driven Brands Holdings Among 3 Stocks Priced Below Estimated Fair Value

BeiGene Receives Positive CHMP Opinion for TEVIMBRA® as a First-Line Treatment for Extensive-Stage Small Cell Lung Cancer

Business Wire

2 months ago

BeiGene Receives Positive CHMP Opinion for TEVIMBRA® as a First-Line Treatment for Extensive-Stage Small Cell Lung Cancer

Exploring 3 High Growth Tech Stocks In The US Market

Simply Wall St.

2 months ago

Exploring 3 High Growth Tech Stocks In The US Market

EXCLUSIVE: Indaptus Therapeutics Starts Phase 1 Combination Study of Decoy20 With BeiGene's Cancer Drug For Advanced Solid Tumors

Benzinga

2 months ago

EXCLUSIVE: Indaptus Therapeutics Starts Phase 1 Combination Study of Decoy20 With BeiGene's Cancer Drug For Advanced Solid Tumors

MT Newswires

3 months ago

Beigene Insider Sold Shares Worth $2,073,826, According to a Recent SEC Filing

Thomson Reuters StreetEvents

3 months ago

Q4 2024 Zymeworks Inc Earnings Call

MT Newswires

3 months ago

Beigene Insider Sold Shares Worth $24,674,638, According to a Recent SEC Filing

FDA Approval For BeiGene (NasdaqGS:ONC) TEVIMBRA In ESCC Shows 34 Percent Death Risk Reduction

Simply Wall St.

3 months ago

FDA Approval For BeiGene (NasdaqGS:ONC) TEVIMBRA In ESCC Shows 34 Percent Death Risk Reduction

FDA approves BeiGene’s Tevimbra plus chemo for oesophageal cancer

Pharmaceutical Technology

3 months ago

FDA approves BeiGene’s Tevimbra plus chemo for oesophageal cancer

MT Newswires

3 months ago

BeiGene Says FDA Approves Tevimbra for Esophageal Cancer First-Line Treatment

TEVIMBRA Approved in U.S. for First-line Treatment of Advanced Esophageal Squamous Cell Carcinoma in Combination with Chemotherapy

Business Wire

3 months ago

TEVIMBRA Approved in U.S. for First-line Treatment of Advanced Esophageal Squamous Cell Carcinoma in Combination with Chemotherapy

MT Newswires

3 months ago

Beigene Insider Sold Shares Worth $331,375, According to a Recent SEC Filing

Why BeiGene, Ltd. (ONC) is Skyrocketing So Far in 2025

Insider Monkey

3 months ago

Why BeiGene, Ltd. (ONC) is Skyrocketing So Far in 2025

US$309 - That's What Analysts Think BeiGene, Ltd. (NASDAQ:ONC) Is Worth After These Results

Simply Wall St.

3 months ago

US$309 - That's What Analysts Think BeiGene, Ltd. (NASDAQ:ONC) Is Worth After These Results

Is BeiGene, Ltd. (ONC) The Best Immunology Stock To Buy Now?

Insider Monkey

3 months ago

Is BeiGene, Ltd. (ONC) The Best Immunology Stock To Buy Now?

BeiGene Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

Simply Wall St.

3 months ago

BeiGene Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

BeiGene (ONC) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

Zacks

3 months ago

BeiGene (ONC) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

MT Newswires

3 months ago

Sector Update: Health Care Stocks Decline Premarket Thursday

MT Newswires

3 months ago

BeiGene Ltd BeiGene Q4 Net Loss Narrows, Revenue Rises; 2025 Revenue Guidance Set

BeiGene Announces Fourth Quarter and Full Year 2024 Financial Results and Business Updates

Business Wire

3 months ago

BeiGene Announces Fourth Quarter and Full Year 2024 Financial Results and Business Updates

BeiGene to Present at Upcoming Investor Conferences

Business Wire

3 months ago

BeiGene to Present at Upcoming Investor Conferences

These Biotech Stocks Aren't Profitable But Still Make Elite IBD 50

Investor's Business Daily

3 months ago

These Biotech Stocks Aren't Profitable But Still Make Elite IBD 50

MT Newswires

3 months ago

BeiGene Insider Sold Shares Worth $12,485,045, According to a Recent SEC Filing

US Stocks Trading Below Estimated Value In February 2025

Simply Wall St.

3 months ago

US Stocks Trading Below Estimated Value In February 2025

BeiGene (ONC) Soars 3.2%: Is Further Upside Left in the Stock?

Zacks

3 months ago

BeiGene (ONC) Soars 3.2%: Is Further Upside Left in the Stock?

High Growth Tech Stocks in the United States to Watch

Simply Wall St.

3 months ago

High Growth Tech Stocks in the United States to Watch

HRMY or ONC: Which Is the Better Value Stock Right Now?

Zacks

4 months ago

HRMY or ONC: Which Is the Better Value Stock Right Now?

BeiGene to Announce Fourth Quarter and Full Year 2024 Financial Results on February 27

Business Wire

4 months ago

BeiGene to Announce Fourth Quarter and Full Year 2024 Financial Results on February 27

Is There An Opportunity With BeiGene, Ltd.'s (NASDAQ:ONC) 41% Undervaluation?

Simply Wall St.

4 months ago

Is There An Opportunity With BeiGene, Ltd.'s (NASDAQ:ONC) 41% Undervaluation?

MT Newswires

4 months ago

Beigene Insider Sold Shares Worth $9,424,955, According to a Recent SEC Filing

ImmunityBio and BeiGene partner on Phase III trial of NSCLC treatment combo

Clinical Trials Arena

4 months ago

ImmunityBio and BeiGene partner on Phase III trial of NSCLC treatment combo

MT Newswires

4 months ago

ImmunityBio Partners With BeiGene to Conduct Phase 3 Trial of Lung Cancer Combination Therapy

Discover 3 US Stocks Including Microchip Technology That May Be Trading Below Estimated Fair Value

Simply Wall St.

4 months ago

Discover 3 US Stocks Including Microchip Technology That May Be Trading Below Estimated Fair Value

Exploring High Growth Tech Stocks in January 2025

Simply Wall St.

4 months ago

Exploring High Growth Tech Stocks in January 2025

When Can We Expect A Profit From BeiGene, Ltd. (NASDAQ:ONC)?

Simply Wall St.

4 months ago

When Can We Expect A Profit From BeiGene, Ltd. (NASDAQ:ONC)?

BeiGene Stock Meets 80-Plus RS Rating Benchmark

Investor's Business Daily

5 months ago

BeiGene Stock Meets 80-Plus RS Rating Benchmark

BeiGene (ONC) Moves 8.9% Higher: Will This Strength Last?

Zacks

5 months ago

BeiGene (ONC) Moves 8.9% Higher: Will This Strength Last?

MT Newswires

5 months ago

Beigene Insider Sold Shares Worth $7,370,515, According to a Recent SEC Filing

BeiGene Announces Appointment of Giancarlo Benelli as Head of Europe

Business Wire

5 months ago

BeiGene Announces Appointment of Giancarlo Benelli as Head of Europe

Share on Social Networks: